{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:33:32Z","timestamp":1787315612048,"version":"build-2736575974"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,3]]},"DOI":"10.7759\/cureus.91572","type":"journal-article","created":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T06:09:08Z","timestamp":1756966148000},"source":"Crossref","is-referenced-by-count":1,"title":["Adropin as a Marker in Type 2 Diabetes: Insights Into Diabetic Kidney Disease and Chronic Heart Failure"],"prefix":"10.7759","author":[{"given":"Satyendra K","family":"Sonkar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhusudan","family":"Agrawal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gyanendra K","family":"Sonkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Bhosale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Medhavi","family":"Gautam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akshay","family":"Pradhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satish","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak","family":"Bhagchandani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32279-7","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"392","author":"GBD 2017 Disease and Injury Incidence and Prevalence Collaborators","year":"2018","unstructured":"GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018, 392:1789-858. 10.1016\/S0140-6736(18)32279-7","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfz058","article-title":"Chronic kidney disease, heart failure and neprilysin inhibition","volume":"35","author":"Haynes R","year":"2020","unstructured":"Haynes R, Zhu D, Judge PK, Herrington WG, Kalra PA, Baigent C. Chronic kidney disease, heart failure and neprilysin inhibition. Nephrol Dial Transplant. 2020, 35:558-64. 10.1093\/ndt\/gfz058","journal-title":"Nephrol Dial Transplant"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11237041","article-title":"Heart failure and cardiorenal syndrome: a narrative review on pathophysiology, diagnostic and therapeutic regimens-from a cardiologist\u2019s view","volume":"11","author":"Mitsas AC","year":"2022","unstructured":"Mitsas AC, Elzawawi M, Mavrogeni S, et al.. Heart failure and cardiorenal syndrome: a narrative review on pathophysiology, diagnostic and therapeutic regimens-from a cardiologist\u2019s view. J Clin Med. 2022, 11:7041. 10.3390\/jcm11237041","journal-title":"J Clin Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.121.052792","article-title":"Evidence-based medical therapy in patients with heart failure with reduced ejection fraction and chronic kidney disease","volume":"145","author":"Beldhuis IE","year":"2022","unstructured":"Beldhuis IE, Lam CS, Testani JM, Voors AA, Van Spall HG, Ter Maaten JM, Damman K. Evidence-based medical therapy in patients with heart failure with reduced ejection fraction and chronic kidney disease. Circulation. 2022, 145:693-712. 10.1161\/CIRCULATIONAHA.121.052792","journal-title":"Circulation"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.11491116","article-title":"Diabetic kidney disease: challenges, progress, and possibilities","volume":"12","author":"Alicic RZ","year":"2017","unstructured":"Alicic RZ, Rooney MT, Tuttle KR. Diabetic kidney disease: challenges, progress, and possibilities. Clin J Am Soc Nephrol. 2017, 12:2032-45. 10.2215\/CJN.11491116","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(82)92450-3","article-title":"Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus","volume":"26","author":"Viberti GC","year":"1982","unstructured":"Viberti GC, Hill RD, Jarrett RJ, Argyropoulos A, Mahmud U, Keen H. Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus. Lancet. 1982, 26:1430-2. 10.1016\/s0140-6736(82)92450-3","journal-title":"Lancet"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvac013","article-title":"Global burden of heart failure: a comprehensive and updated review of epidemiology","volume":"118","author":"Savarese G","year":"2023","unstructured":"Savarese G, Becher PM, Lund LH, Seferovic P, Rosano GM, Coats AJ. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc Res. 2023, 118:3272-87. 10.1093\/cvr\/cvac013","journal-title":"Cardiovasc Res"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3343\/alm.2023.43.3.225","article-title":"Biomarkers in heart failure: from research to clinical practice","volume":"43","author":"Berezin AE","year":"2023","unstructured":"Berezin AE, Berezin AA. Biomarkers in heart failure: from research to clinical practice. Ann Lab Med. 2023, 43:225-36. 10.3343\/alm.2023.43.3.225","journal-title":"Ann Lab Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.109.931782","article-title":"Adropin is a novel regulator of endothelial function","volume":"122","author":"Lovren F","year":"2010","unstructured":"Lovren F, Pan Y, Quan A, et al.. Adropin is a novel regulator of endothelial function. Circulation. 2010, 122:S185-92. 10.1161\/CIRCULATIONAHA.109.931782","journal-title":"Circulation"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23158318","article-title":"Adropin's role in energy homeostasis and metabolic disorders","volume":"23","author":"Ali II","year":"2022","unstructured":"Ali II, D'Souza C, Singh J, Adeghate E. Adropin's role in energy homeostasis and metabolic disorders. Int J Mol Sci. 2022, 23:8318. 10.3390\/ijms23158318","journal-title":"Int J Mol Sci"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/6038261","article-title":"Association of serum adropin concentrations with diabetic nephropathy","volume":"2016","author":"Hu W","year":"2016","unstructured":"Hu W, Chen L. Association of serum adropin concentrations with diabetic nephropathy. Mediators Inflamm. 2016, 2016:6038261. 10.1155\/2016\/6038261","journal-title":"Mediators Inflamm"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1159\/000500106","article-title":"Serum adropin levels are reduced in patients with coronary artery disease","volume":"28","author":"Kutlu O","year":"2019","unstructured":"Kutlu O, Altun \u00d6, Dikker O, et al.. Serum adropin levels are reduced in patients with coronary artery disease. Med Princ Pract. 2019, 28:463-9. 10.1159\/000500106","journal-title":"Med Princ Pract"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1186\/s12902-022-01233-x","article-title":"Regulation of adropin by sitagliptin monotherapy in participants with newly diagnosed type 2 diabetes","volume":"22","author":"Wang Q","year":"2022","unstructured":"Wang Q, An Y, Zhang L, Zhang Y, Wang G, Liu J. Regulation of adropin by sitagliptin monotherapy in participants with newly diagnosed type 2 diabetes. BMC Endocr Disord. 2022, 22:306. 10.1186\/s12902-022-01233-x","journal-title":"BMC Endocr Disord"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1113\/EP089371","article-title":"Improved blood pressure and flow-mediated dilatation via increased plasma adropin and nitrate\/nitrite induced by high-intensity interval training in patients with type 2 diabetes","volume":"107","author":"Davoodi M","year":"2022","unstructured":"Davoodi M, Hesamabadi BK, Ariabood E, et al.. Improved blood pressure and flow-mediated dilatation via increased plasma adropin and nitrate\/nitrite induced by high-intensity interval training in patients with type 2 diabetes. Exp Physiol. 2022, 107:813-24. 10.1113\/EP089371","journal-title":"Exp Physiol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-18086-3","article-title":"Aerobic exercise improves endothelial function and serum adropin levels in obese adolescents independent of body weight loss","volume":"7","author":"Zhang H","year":"2017","unstructured":"Zhang H, Jiang L, Yang YJ, et al.. Aerobic exercise improves endothelial function and serum adropin levels in obese adolescents independent of body weight loss. Sci Rep. 2017, 7:17717. 10.1038\/s41598-017-18086-3","journal-title":"Sci Rep"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12062231","article-title":"Adropin predicts chronic kidney disease in type 2 diabetes mellitus patients with chronic heart failure","volume":"12","author":"Berezina TA","year":"2023","unstructured":"Berezina TA, Obradovic Z, Boxhammer E, Berezin AA, Lichtenauer M, Berezin AE. Adropin predicts chronic kidney disease in type 2 diabetes mellitus patients with chronic heart failure. J Clin Med. 2023, 12:2231. 10.3390\/jcm12062231","journal-title":"J Clin Med"},{"key":"ref17","article-title":"Adropin-a novel biomarker of heart disease: a systematic review article","volume":"45","author":"Yosaee S","year":"2016","unstructured":"Yosaee S, Soltani S, Sekhavati E, Jazayeri S. Adropin-a novel biomarker of heart disease: a systematic review article. Iran J Public Health. 2016, 45:1568-76.","journal-title":"Iran J Public Health"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.4103\/jdmimsu.jdmimsu_425_21","article-title":"Evaluation of serum adropin levels in type 2 diabetic patients and its correlation with insulin resistance: a tertiary care teaching hospital-based study","volume":"16","author":"Shah N","year":"2021","unstructured":"Shah N, Anand P, Kumar S, Kulkarni PA. Evaluation of serum adropin levels in type 2 diabetic patients and its correlation with insulin resistance: a tertiary care teaching hospital-based study. J Datta Meghe Inst Med Sci Univ. 2021, 16:658-61. 10.4103\/jdmimsu.jdmimsu_425_21","journal-title":"J Datta Meghe Inst Med Sci Univ"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1186\/s12902-023-01327-0","article-title":"Circulating levels of adropin and diabetes: a systematic review and meta-analysis of observational studies","volume":"23","author":"Soltani S","year":"2023","unstructured":"Soltani S, Beigrezaei S, Malekahmadi M, Clark CC, Abdollahi S. Circulating levels of adropin and diabetes: a systematic review and meta-analysis of observational studies. BMC Endocr Disord. 2023, 23:73. 10.1186\/s12902-023-01327-0","journal-title":"BMC Endocr Disord"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1159\/000519173","article-title":"The clinical value of serum adropin level in early detection of diabetic nephropathy","volume":"46","author":"Es-Haghi A","year":"2021","unstructured":"Es-Haghi A, Al-Abyadh T, Mehrad-Majd H. The clinical value of serum adropin level in early detection of diabetic nephropathy. Kidney Blood Press Res. 2021, 46:734-40. 10.1159\/000519173","journal-title":"Kidney Blood Press Res"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-2194","article-title":"Low circulating adropin concentrations with obesity and aging correlate with risk factors for metabolic disease and increase after gastric bypass surgery in humans","volume":"97","author":"Butler AA","year":"2012","unstructured":"Butler AA, Tam CS, Stanhope KL, et al.. Low circulating adropin concentrations with obesity and aging correlate with risk factors for metabolic disease and increase after gastric bypass surgery in humans. J Clin Endocrinol Metab. 2012, 97:3783-91. 10.1210\/jc.2012-2194","journal-title":"J Clin Endocrinol Metab"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S243755","article-title":"Promotion of adropin expression by hyperglycemia is associated with STAT3 activation in diabetic rats","volume":"13","author":"Kuo FY","year":"2020","unstructured":"Kuo FY, Cheng KC, Li Y, Cheng JT, Tsai CC. Promotion of adropin expression by hyperglycemia is associated with STAT3 activation in diabetic rats. Diabetes Metab Syndr Obes. 2020, 13:2269-77. 10.2147\/DMSO.S243755","journal-title":"Diabetes Metab Syndr Obes"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2015.01.005","article-title":"Therapeutic effects of adropin on glucose tolerance and substrate utilization in diet-induced obese mice with insulin resistance","volume":"4","author":"Gao S","year":"2015","unstructured":"Gao S, McMillan RP, Zhu Q, Lopaschuk GD, Hulver MW, Butler AA. Therapeutic effects of adropin on glucose tolerance and substrate utilization in diet-induced obese mice with insulin resistance. Mol Metab. 2015, 4:310-24. 10.1016\/j.molmet.2015.01.005","journal-title":"Mol Metab"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.4149\/bll_2016_020","article-title":"Antidiabetic and hypolipidemic effects of adropinin streoptozotocin-induced type 2 diabetic rats","volume":"117","author":"Akcilar R","year":"2016","unstructured":"Akcilar R, Kocak FE, Simsek H, Akcilar A, Bayat Z, Ece E, Kokdasgil H. Antidiabetic and hypolipidemic effects of adropinin streoptozotocin-induced type 2 diabetic rats. Bratisl Lek Listy. 2016, 117:100-5. 10.4149\/bll_2016_020","journal-title":"Bratisl Lek Listy"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.3109\/10520295.2013.821713","article-title":"Immunohistochemical expressions of adropin and \u0131nducible nitric oxide synthase in renal tissues of rats with streptozotocin-\u0131nduced experimental diabetes","volume":"89","author":"Kuloglu T","year":"2014","unstructured":"Kuloglu T, Aydin S. Immunohistochemical expressions of adropin and \u0131nducible nitric oxide synthase in renal tissues of rats with streptozotocin-\u0131nduced experimental diabetes. Biotech Histochem. 2014, 89:104-10. 10.3109\/10520295.2013.821713","journal-title":"Biotech Histochem"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.50.5163","article-title":"Elevated plasma levels of adropin in heart failure patients","volume":"50","author":"Lian W","year":"2011","unstructured":"Lian W, Gu X, Qin Y, Zheng X. Elevated plasma levels of adropin in heart failure patients. Intern Med. 2011, 50:1523-7. 10.2169\/internalmedicine.50.5163","journal-title":"Intern Med"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1007\/s11010-013-1660-4","article-title":"Expression of adropin in rat brain, cerebellum, kidneys, heart, liver, and pancreas in streptozotocin-induced diabetes","volume":"380","author":"Aydin S","year":"2013","unstructured":"Aydin S, Kuloglu T, Aydin S, et al.. Expression of adropin in rat brain, cerebellum, kidneys, heart, liver, and pancreas in streptozotocin-induced diabetes. Mol Cell Biochem. 2013, 380:73-81. 10.1007\/s11010-013-1660-4","journal-title":"Mol Cell Biochem"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.3390\/cells10113259","article-title":"The contribution of cardiac fatty acid oxidation to diabetic cardiomyopathy severity","volume":"10","author":"Karwi QG","year":"2021","unstructured":"Karwi QG, Sun Q, Lopaschuk GD. The contribution of cardiac fatty acid oxidation to diabetic cardiomyopathy severity. Cells. 2021, 10:3259. 10.3390\/cells10113259","journal-title":"Cells"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/392668-adropin-as-a-marker-in-type-2-diabetes-insights-into-diabetic-kidney-disease-and-chronic-heart-failure","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T06:09:11Z","timestamp":1756966151000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/392668-adropin-as-a-marker-in-type-2-diabetes-insights-into-diabetic-kidney-disease-and-chronic-heart-failure"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,3]]},"references-count":28,"URL":"https:\/\/doi.org\/10.7759\/cureus.91572","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9,3]]}}}